Comparison of Neoadjuvant Chemotherapy, Chemoimmunotherapy, and Upfront Radical Cystectomy in High-Risk Bladder Cancer: A Single-Center Retrospective Study
Open Access
- 1 January 2026
- journal article
- Published by Tech Science Press in Oncology Research
- Vol. 34 (10) , 1-10
Abstract
Background: While radical cystectomy is standard for muscle-invasive bladder cancer (MIBC), micrometastasis-related recurrence is common. Cisplatin-based neoadjuvant therapy (NAT) confers modest benefits, while immune checkpoint inhibitors (ICIs) provide new efficacy-enhancing strategies. This study aims to compare the efficacy and safety of ICIs with chemotherapy (NAC-ICI), neoadjuvant chemotherapy (NAC), and no neoadjuvant therapy (NNAT). It also explores potential biomarkers predictive of NAT response and evaluates the real-world efficacy of NAC-IC. Method: This single-center retrospective analysis included 80 radical cystectomy patients, with 51 NNAT group and 29 in the NAT group. Survival outcomes were evaluated by Kaplan-Meier survival curves, with log-rank test and restricted mean survival time (RMST) for comparisons. Pathological responses were assessed by complete response (pCR) and downstaging (pDS). Treatment-related adverse events (TRAEs) and predictive hematological biomarkers were analyzed. Results: Kaplan-Meier curves showed NAT is non-significant survival advantage over NNAT (p = 0.30). The RMST analysis showed the NAC-ICI had significantly longer RMST than the NNAT (56.00 vs. 47.73 months; Δ = +8.27 months; p = 0.0008). Fisher’s exact test showed that NAC-ICI had a numerically higher pCR rate (42.10%) than NAC (20.00%), but the difference was non-significant (p = 0.414) ROC analysis showed baseline platelet count (PLT) was a significant negative predictor of pCR after NAC-ICI. Conclusions: This study indicates potential feasibility and safety of NAT for MIBC patients. Chemoimmunotherapy trends toward better pathological and survival outcomes than chemotherapy alone, but no statistically significant differences were observed. Baseline PLT may be a potential prdictive biomarker.Keywords
This publication has 56 references indexed in Scilit:
- Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based AnalysisClinical Genitourinary Cancer, 2025
- Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesCancer Cell, 2025
- Circulating tumor DNA in muscle-invasive bladder cancer: A systematic reviewActas Urológicas Españolas (English Edition), 2025
- A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant TherapyAdvances in Radiation Oncology, 2024
- Prognostic Value of NLR, PLR, SII, and dNLR in Urothelial Bladder Cancer Following Radical CystectomyClinical Genitourinary Cancer, 2024
- Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world studyClinical and Translational Oncology, 2024
- Platinum-based chemotherapy for early triple-negative breast cancerCochrane Database of Systematic Reviews, 2023
- Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 studyCancer Medicine, 2023
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung CancerJAMA Oncology, 2021
- Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment optionsCancer Treatment Reviews, 2020